Ke­to in a pill? Jim Mel­lon de­buts an­ti-ag­ing joint ven­ture with the Buck ded­i­cat­ed to in­duc­ing ke­to­sis

Jim Mel­lon

Click on the im­age to see the full-sized ver­sion


Jim Mel­lon’s crew at Ju­ve­nes­cence has found its lat­est ven­ture idea in a pop­u­lar di­et mak­ing its rounds in biotech cir­cles.

Er­ic Verdin

Once again team­ing up with the Buck In­sti­tute for Re­search on Ag­ing, Ju­ve­nes­cence has launched BHB Ther­a­peu­tics to ex­plore pre­ven­ta­tive med­i­cines that have po­ten­tial to pro­tect against age-re­lat­ed dis­ease by in­duc­ing a state of ke­to­sis, where the body burns fat in­stead of carbs, spurring the pro­duc­tion of an­ti-in­flam­ma­to­ry ke­tone bod­ies.

In par­tic­u­lar, the biotech start­up will fo­cus on the ke­tone body be­ta-hy­drox­y­bu­tyrate, or — you guessed it — BHB. Er­ic Verdin, the Buck pres­i­dent and CEO whose re­search in­spired an­oth­er Ju­ve­nes­cence spin­out, has dis­cov­ered that BHB helps the body re­spond to stress.

John New­man

A ke­to­genic di­et — which has been her­ald­ed for its ef­fects in weight loss, hunger sup­pres­sion as well as con­cen­tra­tion — and the con­se­quent longterm ex­po­sure to ke­tone bod­ies can al­so ex­tend healthy lifes­pan in mod­el sys­tems, Verdin and col­lab­o­ra­tor John New­man found.

The duo has gen­er­at­ed “hard sci­en­tif­ic da­ta” in mice that show ke­to­sis can be car­dio-pro­tec­tive, CEO Greg Bai­ley told End­points News. Ob­vi­ous­ly, they have a long way to go.

“The rea­son we think that car­dio-pro­tec­tion may trans­late to hu­mans is be­cause if giv­en sug­ar or ke­tones, many peo­ple’s hearts pre­fer ke­tones, where­as the brain is the op­po­site,” he said. “If giv­en the op­tion be­tween sug­ar or ke­tones, the brain will take sug­ar. Un­for­tu­nate­ly, in­di­vid­u­als when they hit 50 (plus or mi­nus a cou­ple years) they be­come in­sulin re­sis­tant — and then the sug­ar can go se­ri­ous­ly high in a va­ri­ety of or­gans and that leads to a va­ri­ety of dif­fer­ent patholo­gies.”

The com­pa­ny is look­ing to be­gin “ag­gres­sive safe­ty stud­ies” in the near-term, Bai­ley added. Should the com­pounds be found safe, he plans to take al­ter­na­tive routes rather than the con­ven­tion­al reg­u­la­to­ry path­way — which he be­lieves can lead to quick­er hu­man test­ing.

Greg Bai­ley

Just days ago, Ju­ve­nes­cence un­veiled the first $46 mil­lion tranche of a promised $100 mil­lion raise that’s de­signed to bankroll longevi­ty projects with the col­lec­tive goal of ex­tend­ing the hu­man lifes­pan to 150 years. So far, it’s ticked off stem cell tech and or­gan re­gen­er­a­tion among the fields it’s es­tab­lished it­self through joint ven­tures with AI groups — In­sil­i­co and Ne­tra­mark — and con­trol­ling in­ter­ests in AgeX and Ly­Ge­n­e­sis.

The goal, founder and chair­man Mel­lon said back then, is to have 18 projects un­der­way by the end of the year.

Look for two or three of them to be an­nounced over the next few weeks, Bai­ley said, not­ing that there should al­so be three or four let­ters of in­tent go­ing out short­ly.


With ad­di­tion­al re­port­ing by Na­tal­ie Grover.

Health­care Dis­par­i­ties and Sick­le Cell Dis­ease

In the complicated U.S. healthcare system, navigating a serious illness such as cancer or heart disease can be remarkably challenging for patients and caregivers. When that illness is classified as a rare disease, those challenges can become even more acute. And when that rare disease occurs in a population that experiences health disparities, such as people with sickle cell disease (SCD) who are primarily Black and Latino, challenges can become almost insurmountable.

Jacob Van Naarden (Eli Lilly)

Ex­clu­sives: Eli Lil­ly out to crash the megablock­buster PD-(L)1 par­ty with 'dis­rup­tive' pric­ing; re­veals can­cer biotech buy­out

It’s taken 7 years, but Eli Lilly is promising to finally start hammering the small and affluent PD-(L)1 club with a “disruptive” pricing strategy for their checkpoint therapy allied with China’s Innovent.

Lilly in-licensed global rights to sintilimab a year ago, building on the China alliance they have with Innovent. That cost the pharma giant $200 million in cash upfront, which they plan to capitalize on now with a long-awaited plan to bust up the high-price market in lung cancer and other cancers that have created a market worth tens of billions of dollars.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

David Meek, new Mirati CEO (Marlene Awaad/Bloomberg via Getty Images)

Fresh off Fer­Gene's melt­down, David Meek takes over at Mi­rati with lead KRAS drug rac­ing to an ap­proval

In the insular world of biotech, a spectacular failure can sometimes stay on any executive’s record for a long time. But for David Meek, the man at the helm of FerGene’s recent implosion, two questionable exits made way for what could be an excellent rebound.

Meek, most recently FerGene’s CEO and a past head at Ipsen, has become CEO at Mirati Therapeutics, taking the reins from founding CEO Charles Baum, who will step over into the role of president and head of R&D, according to a release.

FDA hands ac­cel­er­at­ed nod to Seagen, Gen­mab's so­lo ADC in cer­vi­cal can­cer, but com­bo stud­ies look even more promis­ing

Biopharma’s resident antibody-drug conjugate expert Seagen has scored a clutch of oncology approvals in recent years, finding gold in what are known as “third-gen” ADCs. Now, another of their partnered conjugates is ready for prime time.

The FDA on Monday handed an accelerated approval to Seagen and Genmab’s Tivdak (tisotumab vedotin-tftv, or “TV”) in second-line patients with recurrent or metastatic cervical cancer who previously progressed after chemotherapy rather than PD-(L)1 systemic therapy, the companies said in a release.

Dave Lennon, former president of Novartis Gene Therapies

Zol­gens­ma patent spat brews be­tween No­var­tis and Re­genxbio as top No­var­tis gene ther­a­py ex­ec de­parts

Regenxbio, a small licensor of gene therapy viral vectors spun out from the University of Pennsylvania, is now finding itself in the middle of some major league patent fights.

In addition to a patent suit with Sarepta Therapeutics from last September, Novartis, is now trying to push its smaller partner out of the way. The Swiss biopharma licensed Regenxbio’s AAV9 vector for its $2.1 million spinal muscular atrophy therapy Zolgensma.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 117,700+ biopharma pros reading Endpoints daily — and it's free.

Volker Wagner (L) and Jeff Legos

As Bay­er, No­var­tis stack up their ra­dio­phar­ma­ceu­ti­cal da­ta at #ES­MO21, a key de­bate takes shape

Ten years ago, a small Norwegian biotech by the name of Algeta showed up at ESMO — then the European Multidisciplinary Cancer Conference 2011 — and declared that its Bayer-partnered targeted radionuclide therapy, radium-223 chloride, boosted the overall survival of castration-resistant prostate cancer patients with symptomatic bone metastases.

In a Phase III study dubbed ALSYMPCA, patients who were treated with radium-223 chloride lived a median of 14 months compared to 11.2 months. The FDA would stamp an approval on it based on those data two years later, after Bayer snapped up Algeta and christened the drug Xofigo.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 117,700+ biopharma pros reading Endpoints daily — and it's free.

Rafaèle Tordjman (Jeito Capital)

Con­ti­nu­ity and di­ver­si­ty: Rafaèle Tord­j­man's women-led VC firm tops out first fund at $630M

For a first-time fund, Jeito Capital talks a lot about continuity.

Rafaèle Tordjman had spotlighted that concept ever since she started building the firm in 2018, promising to go the extra mile(s) with biotech entrepreneurs while pushing them to reach patients faster.

Coincidentally, the lack of continuity was one of the sore spots listed in a report about the European healthcare sector published that same year by the European Investment Bank — whose fund is one of the LPs, alongside the American pension fund Teacher Retirement System of Texas and Singapore’s Temasek, to help Jeito close its first fund at $630 million (€534 million). As previously reported, Sanofi had chimed in €50 million, marking its first investment in a French life sciences fund.

Mi­rati tri­umphs again in KRAS-mu­tat­ed lung can­cer with a close­ly watched FDA fil­ing now in the cards

After a busy weekend at #ESMO21, which included a big readout for its KRAS drug adagrasib in colon cancer, Mirati Therapeutics is ready to keep the pressure on competitor Amgen with lung cancer data that will undergird an upcoming filing.

In topline results from a Phase II cohort of its KRYSTAL-1 study, adagrasib posted a response rate of 43% in second-line-or-later patients with metastatic non-small cell lung cancer containing a KRAS-G12C mutation, Mirati said Monday.

As­traZeneca, Dai­ichi Sanky­o's ADC En­her­tu blows away Roche's Kad­cy­la in sec­ond-line ad­vanced breast can­cer

AstraZeneca and Japanese drugmaker Daiichi Sankyo think they’ve struck gold with their next-gen ADC drug Enhertu, which has shown some striking data in late-stage breast cancer trials and early solid tumor tests. Getting into earlier patients is now the goal, starting with Enhertu’s complete walkover of a Roche drug in second-line breast cancer revealed Saturday.

Enhertu cut the risk of disease progression or death by a whopping 72% (p=<0.0001) compared with Roche’s ADC Kadcyla in second-line unresectable and/or metastatic HER2-positive breast cancer patients who had previously undergone treatment with a Herceptin-chemo combo, according to interim data from the Phase III DESTINY-Breast03 head-to-head study presented at this weekend’s #ESMO21.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 117,700+ biopharma pros reading Endpoints daily — and it's free.